Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses. 1991

G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
Department of Pharmacology, Université de Montréal, Canada.

In young healthy volunteers diltiazem does not have linear kinetics between single and multiple doses. Elimination half-life increases and gives AUC's and Cmax higher than those predicted from single dose data. Kinetics of diltiazem were assessed in 16 healthy elderly after a single 60 mg dose and in 24 healthy elderly after 60 mg every 8 h for 7 days. Thirteen participants completed both studies. Elimination half-life, AUC0-24, AUC0-infinity, and Cmax were (mean +/- SE) 7.4 (1.2) h, 349 (34) ng/ml.h, 392 (44) ng/ml.h, and 43 (5) ng/ml respectively after a single dose. After multiple doses elimination half-life, AUC0-48, AUC0-infinity, Cmax and Cmin were respectively 5.7 (0.3) h, 974 (107) ng/ml.h, 1022 (108) ng/ml.h, 102 (7) ng/ml and 43 (5) ng/ml. Exploratory statistics on the 13 volunteers common to both studies showed that the ratio of AUC desacetyl-diltiazem (DAD)/AUC diltiazem rose between single and multiple doses while elimination half-life of both diltiazem and N-desmethyl-diltiazem (MA), tmax, and AUC MA/AUC diltiazem were not affected. The conclusion of this study is that elimination half-life of diltiazem does not increase in elderly between single and multiple doses, possibly due to an increased biotransformation into DAD.

UI MeSH Term Description Entries
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
December 1990, The Journal of antimicrobial chemotherapy,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
July 1992, Journal of clinical pharmacology,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
September 1989, Therapeutic drug monitoring,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
March 2006, Journal of clinical pharmacology,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
May 1995, Arzneimittel-Forschung,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
December 1983, British journal of clinical pharmacology,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
October 2012, Clinical pharmacology in drug development,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
January 1991, European journal of drug metabolism and pharmacokinetics,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
May 1987, Antimicrobial agents and chemotherapy,
G Caillé, and S Boucher, and J Spénard, and Z Lakhani, and A Russell, and J Thiffault, and M G Grace
October 1996, Journal of clinical pharmacology,
Copied contents to your clipboard!